Darzalex CASTOR data shine at ASCO

Data presented at the American Society of Clinical Oncology annual meeting revealed a reduced risk of disease progression and higher response rates among patients treated with Darzalex daratumumab plus Velcade bortezomib and dexamethasone vs.

Read the full 346 word article

User Sign In